MedTrace Logo

Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France

NCT02347865 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 777

Last updated 2022-11-14

No results posted yet for this study

Summary

The purpose of the study is to describe the characteristics and management of post menopausal women with osteoporosis treated with Prolia in France, and examine the use of Prolia in routine clinical practice in France

Conditions

  • Post Menopausal Osteoporosis

Interventions

DRUG

AMG 162 - Prolia

500 patients

DRUG

AMG 162 - Prolia

250 patients, one year later

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
40 Years
Max Age
95 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-16
Primary Completion
2017-10-26
Completion
2018-09-27

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02347865 on ClinicalTrials.gov